Dr. Alicia Levey currently serves as Chief Operating Officer at Pionyr Immunotherapeutics. Dr. Levey joined Pionyr in July 2019 and leads business development, business operations, portfolio strategy, and program management, in addition to managing intellectual property and legal functions. Dr. Levey was instrumental in architecting and closing a transformational staged acquisition of Pionyr by Gilead Sciences in 2020 and currently leads Alliance Management for the ongoing collaboration between the two companies. Dr. Levey earned a Ph.D. in Cancer Biology from the Stanford University School of Medicine.
.svg)
